90 related articles for article (PubMed ID: 17888108)
1. Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease.
Gogovor A; Dragomir A; Savoie M; Perreault S
Value Health; 2007; 10(5):431-41. PubMed ID: 17888108
[TBL] [Abstract][Full Text] [Related]
2. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
[TBL] [Abstract][Full Text] [Related]
3. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data.
Lachaine J; Petrella RJ; Merikle E; Ali F
Can J Cardiol; 2008 Apr; 24(4):269-73. PubMed ID: 18401466
[TBL] [Abstract][Full Text] [Related]
4. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Perreault S; Blais L; Dragomir A; Bouchard MH; Lalonde L; Laurier C; Collin J
Eur J Clin Pharmacol; 2005 Oct; 61(9):667-74. PubMed ID: 16151763
[TBL] [Abstract][Full Text] [Related]
5. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention.
Kettani FZ; Dragomir A; Côté R; Roy L; Bérard A; Blais L; Lalonde L; Moreau P; Perreault S
Stroke; 2009 Jan; 40(1):213-20. PubMed ID: 19038916
[TBL] [Abstract][Full Text] [Related]
6. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
Bourgault C; Elstein E; Le Lorier J; Suissa S
CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
[TBL] [Abstract][Full Text] [Related]
7. Impact of adherence to statins on coronary artery disease in primary prevention.
Bouchard MH; Dragomir A; Blais L; Bérard A; Pilon D; Perreault S
Br J Clin Pharmacol; 2007 Jun; 63(6):698-708. PubMed ID: 17214831
[TBL] [Abstract][Full Text] [Related]
8. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
9. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study.
Bourgault C; Sénécal M; Brisson M; Marentette MA; Grégoire JP
J Hum Hypertens; 2005 Aug; 19(8):607-13. PubMed ID: 15920457
[TBL] [Abstract][Full Text] [Related]
10. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive persistence and drug class.
Marentette MA; Gerth WC; Billings DK; Zarnke KB
Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
[TBL] [Abstract][Full Text] [Related]
13. The impact of cardiovascular profile on persistence associated with antihypertensive medications.
Midy F; Rudnichi A
Int J Clin Pract; 2013 Dec; 67(12):1334-41. PubMed ID: 24246212
[TBL] [Abstract][Full Text] [Related]
14. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence with antihypertensive drugs in new patients.
Degli Esposti E; Sturani A; Di Martino M; Falasca P; Novi MV; Baio G; Buda S; Volpe M
J Hum Hypertens; 2002 Jun; 16(6):439-44. PubMed ID: 12037702
[TBL] [Abstract][Full Text] [Related]
16. Patterns of amlodipine and felodipine use in an elderly Quebec population.
Sheehy O; LeLorier J
Can J Cardiol; 2000 Sep; 16(9):1109-17. PubMed ID: 11021955
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
18. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention.
Perreault S; Blais L; Lamarre D; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
Br J Clin Pharmacol; 2005 May; 59(5):564-73. PubMed ID: 15842555
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
20. Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Lachaine J; Rinfret S; Merikle EP; Tarride JE
Am Heart J; 2006 Jul; 152(1):164-9. PubMed ID: 16824851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
